KALA BIO (NASDAQ:KALA) Announces Earnings Results

KALA BIO (NASDAQ:KALA) posted its quarterly earnings results on Tuesday. The company reported ($1.93) EPS for the quarter, beating analysts’ consensus estimates of ($2.43) by $0.50, Zacks reports.

KALA BIO Trading Down 4.1 %

KALA BIO stock traded down $0.29 during midday trading on Wednesday, hitting $6.80. 31,414 shares of the stock were exchanged, compared to its average volume of 84,371. The stock’s 50-day simple moving average is $5.97 and its 200 day simple moving average is $6.29. KALA BIO has a fifty-two week low of $4.21 and a fifty-two week high of $10.97. The company has a current ratio of 3.07, a quick ratio of 3.07 and a debt-to-equity ratio of 1.97. The stock has a market capitalization of $31.35 million, a price-to-earnings ratio of -0.55 and a beta of -2.13.

Wall Street Analyst Weigh In

Separately, Oppenheimer reaffirmed an “outperform” rating and set a $15.00 price objective on shares of KALA BIO in a report on Monday, August 19th.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.